[go: up one dir, main page]

WO1996031206A3 - Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose - Google Patents

Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose Download PDF

Info

Publication number
WO1996031206A3
WO1996031206A3 PCT/US1996/004028 US9604028W WO9631206A3 WO 1996031206 A3 WO1996031206 A3 WO 1996031206A3 US 9604028 W US9604028 W US 9604028W WO 9631206 A3 WO9631206 A3 WO 9631206A3
Authority
WO
WIPO (PCT)
Prior art keywords
coumarins
flavones
atherosclerosis
treatment
agents
Prior art date
Application number
PCT/US1996/004028
Other languages
English (en)
Other versions
WO1996031206A2 (fr
Inventor
Uday Saxena
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to AU52592/96A priority Critical patent/AU5259296A/en
Publication of WO1996031206A2 publication Critical patent/WO1996031206A2/fr
Publication of WO1996031206A3 publication Critical patent/WO1996031206A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Les flavones et les coumarines ou leurs sels pharmaceutiquement acceptables sont des inhibiteurs de VCAM-1 et ICAM-1 et sont donc utiles dans le traitement de l'athérosclérose, de la resténose et de troubles immunitaires tels que l'arthrite et le rejet des transplantations.
PCT/US1996/004028 1995-04-07 1996-03-25 Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose WO1996031206A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52592/96A AU5259296A (en) 1995-04-07 1996-03-25 Flavones and coumarins as agents for the treatment of athero sclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41870995A 1995-04-07 1995-04-07
US08/418,709 1995-04-07

Publications (2)

Publication Number Publication Date
WO1996031206A2 WO1996031206A2 (fr) 1996-10-10
WO1996031206A3 true WO1996031206A3 (fr) 1996-12-12

Family

ID=23659261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004028 WO1996031206A2 (fr) 1995-04-07 1996-03-25 Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose

Country Status (2)

Country Link
AU (1) AU5259296A (fr)
WO (1) WO1996031206A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889698B2 (en) 2007-02-01 2014-11-18 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051307A1 (fr) * 1997-05-13 1998-11-19 Octamer, Inc. METHODES DE TRAITEMENT D'INFLAMMATIONS, D'AFFECTIONS INFLAMMATOIRES, D'ARTHRITE ET D'ACCIDENTS VASCULAIRES CEREBRAUX A L'AIDE D'INHIBITEURS DE pADPRT
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US5922719A (en) * 1997-08-11 1999-07-13 Warner-Lambert Company Coumarin dopamine D4 receptor antagonists
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
AU3653099A (en) * 1998-04-17 1999-11-08 Parker Hughes Institute Btk inhibitors and methods for their identification and use
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
FR2781153B1 (fr) * 1998-07-15 2001-08-03 Lafon Labor Composition therapeutique a base de flavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
DE19845372A1 (de) * 1998-10-02 2000-04-20 Gruenenthal Gmbh Verwendung von Katecholderivaten als Proteinaseninhibitoren
EP1140046A1 (fr) * 1998-12-15 2001-10-10 Warner-Lambert Company Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2000050030A1 (fr) * 1999-02-25 2000-08-31 Ted Ebendal Nouvelle utilisation
AU2001278980A1 (en) * 2000-07-21 2002-02-05 Chugai Seiyaku Kabushiki Kaisha Coumarin derivatives useful as tnfalpha inhibitors
EP1368024A4 (fr) * 2001-03-16 2009-03-18 Novogen Res Pty Ltd Traitement de la restenose
KR20020096368A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 연골세포의 분화촉진, 연골세포의 탈분화 억제 또는탈분화된 연골세포의 재분화 촉진제, 그것의 스크리닝방법 및 그것을 이용한 연골세포의 제조방법
KR20020096367A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 관절염 예방 또는 치료제 및 그것의 스크리닝 방법
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
JP4587652B2 (ja) * 2002-09-09 2010-11-24 株式会社フラバミン 新規フラボノイド化合物及びその利用
CA2497560A1 (fr) 2002-09-20 2004-04-01 Promega Corporation Procedes fondes sur la luminescence et sondes permettant de mesurer l'activite du cytochrome p450
MXPA05004247A (es) * 2002-10-22 2005-10-18 Jenken Biosciences Inc Cromonas y derivados de cromona y usos de los mismos.
EP1558250A4 (fr) 2002-10-30 2006-11-02 Merck & Co Inc Modulateurs gamma-aminoamides de l'activite de recepteur de chimiokine
WO2004105769A1 (fr) * 2003-05-28 2004-12-09 Universite De Liege Composition pharmaceutique destinee au traitement et/ou a la prevention de l'atherosclerose d'origine infectieuse
ES2431524T3 (es) 2004-04-13 2013-11-26 Incyte Corporation Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas
EP2272972A1 (fr) 2005-05-31 2011-01-12 Promega Corporation Composés luminogènes et fluorogènes et procédés pour la détection de molécules ou de conditions
GB2443576A (en) * 2005-07-15 2008-05-07 Sahajanand Biotech Private Ltd Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis
CA2617213C (fr) * 2005-07-29 2014-01-28 Resverlogix Corp. Compositions pharmaceutiques pour la prevention et le traitement de maladies complexes et leur administration par des dispositifs medicaux inserables
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
CN1837202B (zh) * 2006-04-25 2010-08-18 中国人民解放军第二军医大学 具有降血脂作用的黄酮醇类化合物
WO2009118338A2 (fr) * 2008-03-27 2009-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d’un composé de type polyphénolique pour prévenir ou traiter une maladie neurodégénérative d’expansion de polyglutamine
WO2009158404A1 (fr) 2008-06-26 2009-12-30 Resverlogix Corp. Procédés de préparation de dérivés de quinazolinone
JP5597200B2 (ja) 2008-08-18 2014-10-01 プロメガ コーポレイション ルミネッセンスを生じる化合物およびチトクロムｐ４５０３ａ酵素を検出するための方法
EP2346865B1 (fr) 2008-09-22 2015-07-15 Merck Canada Inc. Dérivés d'indole comme antagonistes du récepteur crth2
EP2342188B1 (fr) * 2008-09-29 2014-07-30 GlaxoSmithKline LLC Analogues de chroménone en tant que modulateurs de sirtuine
WO2010039815A1 (fr) * 2008-09-30 2010-04-08 Case Western Reserve University Sondes moléculaires pour l’imagerie de la myéline
PT2370442E (pt) 2008-11-26 2013-06-27 Pfizer 3-aminociclopentanocarboxamidas como moduladores de receptor de quimiocina
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
JP2012517426A (ja) 2009-02-09 2012-08-02 アステックス ファーマシューティカルズ インコーポレイテッド ピロロピリミジニルａｘｌキナーゼ阻害剤
PE20120056A1 (es) 2009-02-24 2012-02-05 Merck Sharp & Dohme Derivados de indol como antagonistas del receptor crth2
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
EP2421533B1 (fr) 2009-04-22 2018-10-17 Resverlogix Corp. Nouveaux agents anti-inflammatoires
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
US9469615B2 (en) 2010-12-23 2016-10-18 Merck Sharp & Dohme Corp. Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators
AU2012250958B8 (en) 2011-05-04 2017-02-09 Merck Sharp & Dohme Corp. Amino-pyridine-containing Spleen Tyrosine Kinase (Syk) inhibitors
CN102274237B (zh) * 2011-06-16 2012-12-05 成都中医药大学 黄酮类化合物的新用途
WO2012174176A1 (fr) 2011-06-17 2012-12-20 Merck Sharp & Dohme Corp. Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
EP2935253B1 (fr) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Nouveaux composés hétérocycliques en tant qu'inhibiteurs de bromodomaine
WO2015116867A1 (fr) 2014-01-29 2015-08-06 Promega Corporation Sondes masquées par quinone utilisées comme réactifs de marquage pour mesurer l'absorption cellulaire
US9840488B2 (en) * 2015-01-26 2017-12-12 Utah State University Carbon monoxide releasing molecules and associated methods
GB2585171B (en) 2015-02-19 2021-03-24 Council Scient Ind Res An antioxidant compound having anti atherosclerotic effect and preparation thereof
EP3268007B1 (fr) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
KR101837690B1 (ko) * 2016-04-04 2018-03-13 한국한의학연구원 고량강 추출물, 이의 분획물 또는 고량강으로부터 분리된 화합물 갈란진을 유효성분으로 포함하는 혈관 재협착 예방 또는 치료용 조성물
DE102016223763A1 (de) * 2016-11-30 2018-05-30 Beiersdorf Ag Verwendung von 2’-Methoxyflavon in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
CN109265424B (zh) * 2018-09-25 2020-08-21 天津中医药大学 一种黄酮类衍生物及其制备方法和鉴定方法
CN113330013B (zh) 2019-01-10 2022-12-27 石药集团中奇制药技术（石家庄）有限公司 杂环化合物盐及其应用
CN115160279B (zh) * 2022-07-27 2023-11-24 中国药科大学 苯并吡喃酮类化合物、药物组合物和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175808A (en) * 1967-11-24 1969-12-23 Laroche Navarron Lab Improvements in or relating to new Therapeutic Composition, new Coumarin Derivatives and their process of preparation
FR2244493A1 (en) * 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE3601417A1 (de) * 1986-01-20 1987-07-23 Nattermann A & Cie 2'-alkyl-(alkenyl-) substituierte quercetine
EP0347864A2 (fr) * 1988-06-24 1989-12-27 Andries Johannes Cornelus Strydom Agents antiathérogéniques
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
EP0564350A1 (fr) * 1992-03-31 1993-10-06 Adir Et Compagnie Nouvelles 3',5'-ditertbutyl-4'-hydroxy flavones, leur procédé de préparation et les compositions pharmaceutiques exerçant une activité anti-oxydante et anti-vasoconstrictrice
EP0633022A2 (fr) * 1993-07-09 1995-01-11 Kureha Chemical Industry Co., Ltd. Flavones chondroprotectives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175808A (en) * 1967-11-24 1969-12-23 Laroche Navarron Lab Improvements in or relating to new Therapeutic Composition, new Coumarin Derivatives and their process of preparation
FR2244493A1 (en) * 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE3601417A1 (de) * 1986-01-20 1987-07-23 Nattermann A & Cie 2'-alkyl-(alkenyl-) substituierte quercetine
EP0347864A2 (fr) * 1988-06-24 1989-12-27 Andries Johannes Cornelus Strydom Agents antiathérogéniques
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
EP0564350A1 (fr) * 1992-03-31 1993-10-06 Adir Et Compagnie Nouvelles 3',5'-ditertbutyl-4'-hydroxy flavones, leur procédé de préparation et les compositions pharmaceutiques exerçant une activité anti-oxydante et anti-vasoconstrictrice
EP0633022A2 (fr) * 1993-07-09 1995-01-11 Kureha Chemical Industry Co., Ltd. Flavones chondroprotectives

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A. DE NEELING: "Coumarine bij atherosclerose", NED. TIJDSCHR. GENEESKD., vol. 119, no. 117, 26 April 1975 (1975-04-26), pages 673 - 677, XP000575659 *
Conference on "Molecular and Clinical Implications for Allergy in the 21st Century" in Nantucket, Massachusetts September 25-29, 1994 *
E. MIDDLETON ET AL.: "Quercetin inhibits lipopolysaccharide-induced expression of endothelial cell intracellular adhesion molecule-1", INT. ARCH. ALLERGY IMMUNOL., vol. 107, no. 1-3, 13 July 1995 (1995-07-13), pages 435 - 436, XP000576204 *
E. SEMPINSKA ET AL.: "Effect of flavonoids on the platelet adhesivness in repeatedly bred rats", POL. J. PHARMACOL. PHARM., vol. 29, no. 1, 1977, pages 7 - 10, XP000575657 *
H.K. NIEUWENHUIS ET AL.: "Agents interfering with the platelet-vessel wall interaction", PHARM. WEEKBL. SCI., vol. 6, no. 1, 24 February 1984 (1984-02-24), pages 27 - 31, XP000575665 *
M.E. GERRITSEN ET AL.: "Flavonoids inhibit cytokine.induced endothelial cell adhesion protein gene expression", AM. J. PATHOLOGY, vol. 147, no. 2, 2 August 1995 (1995-08-02), pages 278 - 292, XP000575649 *
S. TRANCHINA ET AL.: "Inhibition of human monocyte adhesion to endothelial cells by the coumarin derivative, chloricromene", BR. J. PHARMACOL., vol. 111, no. 2, 1994, pages 578 - 581, XP000575658 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889698B2 (en) 2007-02-01 2014-11-18 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases

Also Published As

Publication number Publication date
WO1996031206A2 (fr) 1996-10-10
AU5259296A (en) 1996-10-23

Similar Documents

Publication Publication Date Title
WO1996031206A3 (fr) Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose
FI955315L (fi) HIV:n proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDS'n hoitoon
AU1382299A (en) Method and apparatus for treating stenosis of the carotid artery
HUT72166A (en) Herbicides containing 4-benzoylisoxazole derivatives and process for producing the active ingredient
EP0678285A3 (fr) Implant orthopédique et procédé pour le fabriquer.
AU2103295A (en) Methods for the treatment of thrombosis
EP1006960A4 (fr) Support orthopedique confortable et son procede de production
AU6023596A (en) Process and product for the treatment of arthritis
DE69209043D1 (de) Walzwerk, Walzverfahren und Walzwerksystem
EP0870730A4 (fr) Octahedrite stable et son procede de preparation
DE69404527D1 (de) Walzwerk und Verfahren
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
EP0636385A3 (fr) Méthode et système de cardioversion post-opératoire.
DE69009362D1 (de) Walzwerk und Walzverfahren.
SG63607A1 (en) Process and plant for generating nitrogen for heat treatment
ITTO940100A0 (it) Impianto per la formatura di articoli in vetro.
DE69822676D1 (de) Walzanlage und Walzverfahren
EP0953674A4 (fr) Similicuir du type nubuck et son procede de fabrication
ATE215783T1 (de) Gefrorenes konzentriertes milchprodukt und verfahren zu dessen herstellung
ZA988785B (en) Cobalt-based alloy article produced from the alloy and process for the manufacture thereof
EP0622879A3 (fr) Laser à semi-conducteur et méthode de fabrication.
CY2427B1 (en) Use of granisetron for the treatment of post-operative nausea and vomiting.
DE69715858D1 (de) Intraokularlinsen und dessen herstellungsvefahren
EP0627709A3 (fr) Procédé et système pour l'élimination des produits fabriqués.
PT1152762E (pt) Utilizacao de desoxipeganina no tratamento da demencia de alzheimer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG CA CN CZ EE GE HU JP KR LT LV MX NO NZ PL RO SG SI SK UA UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG CA CN CZ EE GE HU JP KR LT LV MX NO NZ PL RO SG SI SK UA UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA